The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 23, 2018
Filed:
May. 03, 2013
Applicant:
Cornell University, Ithaca, NY (US);
Inventor:
Pengbo Zhou, Princeton Junction, NJ (US);
Assignee:
CORNELL UNIVERSITY, Ithaca, NY (US);
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); A61K 31/4745 (2006.01); A61K 31/496 (2006.01); A61K 31/7105 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/4745 (2013.01); A61K 31/496 (2013.01); A61K 31/7105 (2013.01); C12N 15/113 (2013.01); G01N 33/57407 (2013.01); G01N 33/57484 (2013.01); C12N 2310/14 (2013.01); C12N 2320/31 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/52 (2013.01);
Abstract
The current disclosure describes materials and methods for identifying subjects that would benefit from treatment with a DNA topoisomerase 1 inhibitor, based on the levels of cullin 4B gene, RNA and protein levels in the subject. The disclosure identifies CUL4B as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents. The current disclosure also identifies novel therapeutic agents that modulate the level of CUL4B expression, and sensitize a subject to treatment with a second therapeutic agent.